REGN Q2 2022 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.9B-44.4% YoY

Gross Profit

$2.5B87.0% margin

Operating Income

$1.3B45.7% margin

Net Income

$852M29.8% margin

EPS (Diluted)

$7.47

QoQ Revenue Growth

-3.6%

Cash Flow

Operating Cash Flow

$564M

Free Cash Flow

$411M

Stock-Based Comp.

$160M

Balance Sheet

Total Assets

$27.2B

Total Liabilities

$6.5B

Stockholders' Equity

$20.7B

Cash & Equivalents

$3.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.9B	$5.1B	-44.4%
Gross Profit	$2.5B	$4.4B	-43.2%
Operating Income	$1.3B	$3.3B	-61.0%
Net Income	$852M	$3.1B	-72.5%

Revenue Segments

Product

$1.8B61%

Collaboration Revenue

$1.0B37%

Product and Service, Other

$59M2%